Skip to main content

Cassava Sciences Inc(SAVA-Q)
NASDAQ

Today's Change
Delayed Last Update
Day Low2.19
Day High2.49
Open:2.19
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Tipranks
Cassava Sciences Rebrands as Filana Therapeutics, Updates Ticker
GlobeNewswire
Cassava Sciences Announces Name Change to Filana Therapeutics, Inc.
Tipranks
Cassava Sciences DOJ Inquiry Closed, Legal Overhang Eased
GlobeNewswire
Cassava Announces Closure of U.S. Department of Justice Investigation
GlobeNewswire
Cassava Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer’s Disease in the Journal of Prevention of Alzheimer’s Disease
Tipranks
Cassava Sciences Reaches Settlement in Securities Class Action
GlobeNewswire
Cassava Announces Agreement to Settle Securities Class Action Litigation
Tipranks
FDA Places Clinical Hold on Cassava’s Epilepsy Trial
Tipranks
Cassava Sciences Approves Executive Cash Bonuses for 2025
Tipranks
Cassava Sciences Submits IND Application for Simufilam
Tipranks
Cassava Sciences Reports Q3 2025 Financials and Advances Simufilam
GlobeNewswire
Cassava Reports Q3 2025 Financials Results and Provides Business Update
Tipranks
Cassava Sciences’ Legal Victory Clears Research Path
Tipranks
Cassava Sciences Appoints Dawn C. Bir to Board
Business Wire
Halper Sadeh LLC Encourages Cassava Sciences, Inc. Shareholders to Contact the Firm to Discuss Their Rights
Tipranks
Cassava Sciences Releases New Corporate Presentation
GlobeNewswire
Cassava Sciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Tipranks
Cassava Sciences Advances Simufilam for Epilepsy Treatment
Motley Fool
Cassava Sciences Posts Q2 Loss on Pivot
GlobeNewswire
Cassava Reports Q2 2025 Financials Results and Provides Business Update
GlobeNewswire
Cassava Sciences Appoints Dr. Joseph Hulihan as Chief Medical Officer
Tipranks
Cassava Sciences Announces Positive Preclinical Results
GlobeNewswire
Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy
Tipranks
Cassava Sciences Reveals Promising Simufilam Preclinical Data
GlobeNewswire
Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development
GlobeNewswire
Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data
GlobeNewswire
Cassava Sciences Reports 2024 Financial Results and Provides Business Update
GlobeNewswire
Cassava Sciences Licenses Simufilam Method of Treatment Patent
TheNewswire.com
Final SAVA Deadline Reminder: February 10, 2025 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP
TheNewswire.com
SAVA Deadline in 1 Day: Kessler Topaz Meltzer & Check, LLP Reminds Cassava Sciences, Inc. (SAVA) Investors of Filing Deadline in Class Action Lawsuit
TheNewswire.com
SAVA Deadline in 3 Days: Kessler Topaz Meltzer & Check, LLP Reminds Cassava Sciences, Inc. (SAVA) Investors of Filing Deadline in Class Action Lawsuit
TheNewswire.com
SAVA Deadline in 5 Days: Kessler Topaz Meltzer & Check, LLP Reminds Cassava Sciences, Inc. (SAVA) Investors of Filing Deadline in Class Action Lawsuit

Profile

Cassava Sciences Inc. is focused on the early detection and treatment of neurodegenerative diseases, such as Alzheimer's. Cassava Sciences Inc., formerly known as Pain Therapeutics Inc., is based in Austin, United States.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.